GSK plc
bepirovirsen
chronic hepatitis B
Resolved
102days ago
Approval decision · ~ Mar 27, 2026 estimated
What's at stake
A final FDA approval decision on bepirovirsen for chronic hepatitis B is expected ~ Mar 27, 2026.
Primary source
· SEC 6-K
verified 11h ago
“Bepirovirsen was granted SENKU designation in Japan 3 in August 2024, reflecting its innovation and potential to address a disease with high unmet medical need.”